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Abstract
Background: Anillin (ANLN), an actin-binding protein required for cytokinesis, has recently been presented as part
of a prognostic marker panel in breast cancer. The objective of the current study was to further explore the
prognostic and functional value of ANLN as a single biomarker in breast cancer.
Methods: Immunohistochemical assessment of ANLN protein expression was performed in two well characterized
breast cancer cohorts (n = 484) with long-term clinical follow-up data and the results were further validated at the
mRNA level in a publicly available transcriptomics dataset. The functional relevance of ANLN was investigated in
two breast cancer cell lines using RNA interference.
Results: High nuclear fraction of ANLN in breast tumor cells was significantly associated with large tumor size, high
histological grade, high proliferation rate, hormone receptor negative tumors and poor prognosis in both examined
cohorts. Multivariable analysis showed that the association between ANLN and survival was significantly
independent of age in cohort I and significantly independent of proliferation, as assessed by Ki-67 expression in
tumor cells, age, tumor size, ER and PR status, HER2 status and nodal status in cohort II. Analysis of ANLN mRNA
expression confirmed that high expression of ANLN was significantly correlated to poor overall survival in breast
cancer patients. Consistent with the role of ANLN during cytokinesis, transient knock-down of ANLN protein
expression in breast cancer cell lines resulted in an increase of senescent cells and an accumulation of cells in the
G2/M phase of the cell cycle with altered cell morphology including large, poly-nucleated cells. Moreover, ANLN
siRNA knockdown also resulted in decreased expression of cyclins D1, A2 and B1.
Conclusions: ANLN expression in breast cancer cells plays an important role during cell division and a high fraction
of nuclear ANLN expression in tumor cells is correlated to poor prognosis in breast cancer patients, independent of
Ki-67, tumor size, hormone receptor status, HER2 status, nodal status and age.
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Background
Breast cancer is the most common female malignancy
world-wide and approximately 500 000 women succumb
to the disease annually [1]. In Sweden, approximately 9
100 cases of female malignant breast tumors are diag-
nosed annually. The incidence of breast cancer has
shown an annual increase with 1.4% during the last 20 years,
at least in part due to an ageing population with increased
hormonal replacement therapy and changes in life style,
such as obesity and first pregnancy late in life. Furthermore,
systematic mammographic screening programs and ele-
vated public awareness have led to the detection of more
cases of breast cancer at an early stage. Early detection and
a transition to more individualized targeted therapies, has
resulted in increased recurrence-free and overall survival
rates [2]. Although prognostic gene expression-based
profiles have rapidly evolved, there is a need for
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robust immunohistochemistry (IHC)-based protein bio-
markers that can be introduced into clinical praxis.
The actin-binding protein ANLN is a ubiquitously
expressed protein required for cytokinesis. During the inter-
phase of the cell cycle ANLN is primarily located to the
nucleus. At the onset of mitosis, ANLN protein relocates to
the cytoplasm where it accumulates in the contractile ring
and cleavage furrow during telophase [3]. Recruitment of
ANLN to the cleavage furrow is mediated by RhoA-
dependent mechanisms [4, 5]. Furthermore, ANLN inter-
acts closely with RhoA, stabilizes the localization of the
latter to the cleavage furrow and stimulates the expression
of active RhoA [4, 6]. Numerous additional proteins, includ-
ing F-actin, myosin, septins and CD2AP have been shown
to interact with ANLN during assembly, maintenance and
ingression of the cleavage furrow [7]. Lack of ANLN is
generally associated with correct assembly of the cleavage
furrow but deficiencies during furrow ingression and com-
pletion of cell separation [3, 5].
Consistent with the prominent role of ANLN during
cytokinesis, up-regulation of ANLN expression is frequently
observed during cancer development, growth and progres-
sion [8–10]. It has also been shown that depletion of ANLN
expression in human non-small cell lung cancer cells leads
to suppression of cell proliferation and an increase of large,
poly-nucleated tumor cells [6]. Interestingly, overexpression
of the ANLN protein did not only induce cell growth, but
also enhanced the migratory capacity of cells, implying a
role of ANLN beyond cell cycle control. High ANLN
mRNA expression and nuclear ANLN protein expression
in lung cancer tissue has been shown to be significantly
correlated to poor survival [6, 11]. In another study, cyto-
plasmic immunoreactivity for ANLN in renal cell carcin-
omas was associated with a better prognosis, indicating an
independent function of ANLN in the cytoplasm [12].
Moreover, ANLN mRNA expression was shown to increase
from normal tissue to hyperplasia to malignant and meta-
static disease in breast, ovary, renal, colorectal, hepatic,
lung, endometrial and pancreatic cancer [8].
The relevance of ANLN protein expression in breast
cancer tissue specimens has been explored as a part of a
systematic approach to identify novel prognostic bio-
markers. O’Leary and co-workers [13] found that a moder-
ate to strong nuclear intensity of ANLN expression was
significantly associated with decreased breast cancer spe-
cific survival (BCSS) and recurrence free survival (RFS).
Using multivariable cox regression analysis, ANLN was
suggested as an independent prognostic factor for BCSS
following adjustment for tumor size, nodal status, tumor
grade, hormone receptor status, HER2 status, Ki-67, tumor
type, age and the proteins PDZ-Domain Containing 1
(PDZK1) and PDZ-Binding Kinase (PBK). In a recent study
based on a cohort consisting of 71 patients diagnosed with
primary breast cancer, the rate of ANLN expression was
shown to be significantly higher in breast cancer compared
to normal breast tissue [14]. In this study, ANLN knock-
down was also shown to inhibit cell migration, colony for-
mation and cell cycle progression.
The aim of the present study was to further investigate
and validate the prognostic significance of ANLN expres-
sion in breast cancer. Moreover, the functional role and a
potential treatment predictive value of ANLN expression
in patients with primary breast cancer were explored.
Methods
Patient cohorts
Tissue microarray (TMA) construction, IHC and slide
scanning were performed as previously described [15].
TMAs with tumor samples from two independent breast
cancer cohorts were used to investigate the expression of
ANLN protein by IHC. All formalin-fixed and paraffin-
embedded (FFPE) patient tissue samples were histopatho-
logically re-evaluated on hematoxylin and eosin stained
slides prior to TMA construction. Cohort I consisted of
144 patients diagnosed with breast cancer at Malmö Uni-
versity Hospital, Malmö, Sweden, between 2001 and 2002
[16, 17]. The median age at diagnosis was 65 years (range
34-97) and the median follow-up time for disease specific
and overall survival was 78 months. The second cohort was
comprised of 564 premenopausal breast cancer patients en-
rolled in a randomized tamoxifen treatment trial [18–21].
Between the years 1986 and 1991, premenopausal women
with stage II breast cancer were randomized to either 2
years of tamoxifen treatment (n = 276) or no adjuvant treat-
ment (n = 288) irrespective of hormone receptor status.
The median age at diagnosis, in both treatment groups,
was 45 years (range 26–57 for the control group and range
25–57 for the tamoxifen group). The median follow-up
time for patients without a breast cancer event was
13.9 years. This study was approved by the local Ethics
Committees at Lund and Linköping Universities, whereby
informed consent was deemed not to be required but
opting out was an option (cohort I) and oral informed
consent (cohort II) was registered for included patients.
Immunohistochemistry
The specific target binding of the primary affinity purified
polyclonal antibody towards ANLN (HPA005680, Atlas Anti-
bodies, Stockholm, Sweden) was initially validated according
to standardized procedures used in the Human Protein Atlas
(http://www.proteinatlas.org) with assays including reverse
phase protein array, Western blot, IHC, immunofluorescence
(IF) and comparing results with bioinformatic predictions
and published data [22]. Moreover, this polyclonal ANLN
antibody was further validated by epitope mapping [23].
For IHC analysis of protein expression, TMA blocks were
cut in 4 μm sections using a microtome, Microm HM355S,
with a section transfer system (Thermo Fisher Scientific,
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Waltham, USA) and placed onto Superfrost Plus glass
slides and dried at room temperature over night. Following
that, the slides were baked at 50°C for 12–24 h. Sections
were deparaffinized in Neo-Clear (Merck, Darmstadt,
Germany), hydrated in graded ethanol and blocked for
endogenous peroxidase activity with 0.3% hydrogen perox-
idase (Merck) in an Autostainer XL (Leica Microsystems,
Wetzlar, Germany). Heat induced antigen retrieval was
done by boiling the glass slides in citrate buffer, pH 6.0
(Thermo Fisher Scientific) for 4 min at 125°C in a decloak-
ing chamber (Biocare Medical, CA, USA). Automated IHC
was done as described previously [15] using a Lab Vision
Autostainer 480 (Thermo Fisher Scientific). ANLN anti-
body (Atlas Antibodies) was diluted (1:50) in UltraAb Dilu-
ent (Thermo Fisher Scientific) and incubated on the slides
for 30 min at room temperature. Following incubation with
a secondary anti-rabbit antibody conjugated to a horserad-
ish peroxidase labeled polymer (Thermo Fisher Scientific)
for 30 min at room temperature, the signal was developed
with diaminobenzidine (DAB) mixed with chromogen
(Thermo Fisher Scientific) at 1:40 for 10 min at room
temperature. Counterstaining, dehydration and mounting
were done in an Autostainer XL (Leica Microsystems).
Counterstaining was done with Mayer’s hematoxylin
(Histolab, Gothenburg, Sweden) for 5 min at room
temperature. The slides were washed in water, incubated in
lithium carbonate for 1 min at room temperature, washed
in water and dehydrated in graded ethanol and Neo-Clear
(Merck) followed by automated coverslipping (CV5030,
Leica) with Pertex (Histolab).
Scanning and annotation
The automated scanning system ScanScope XT (Aperio
Technologies, Vista, USA) was used to digitalize IHC stained
slides at 20x magnification. The outcome of immunohisto-
chemical staining was manually annotated by KM, assisted
by two pathologists (FP and KJ), using the Aperio Image-
Scope Viewer v.10.2.1.2314 (Aperio Technologies). Nuclear
staining of ANLN in tumor cells was assessed from both
cores (1 mm diameter) by scanning through the tumor tissue
at high power magnification to estimate the fraction and in-
tensity of positive tumor cell nuclei. The fraction of positive
nuclei (NF) was categorized as 0–1%, 2–10%, 11–25%, 26–
50%, 51–75% or 76–100%, and the nuclear intensity (NI)
was recorded using a 4-graded scale as negative, weak, mod-
erate or strong. Immunohistochemical staining for ANLN
expression showing different levels of ANLN expression is
demonstrated in Fig. 1. High ANLN expression was consid-
ered as NF > 10% independent of nuclear staining intensity.
Cell culture
The functional relevance of ANLN was studied in two
different breast cancer cell lines, one cell line that lacks
ER expression (SKBR3) and one ER expressing cell line
(T47D) (American Type Culture Collection, Manassas,
USA). SKBR3 cells were grown in McCoy’s 5A medium
Fig. 1 ANLN expression in breast cancer. Examples of immunohistochemical staining patterns of ANLN in breast cancer tissue shows nuclear
expression in a variable fraction of tumor cells. Examples correspond to the different scores for nuclear fraction (NF) used in the analysis. 0–1%
(a), 2–10% (b), 11–25% (c), 26–50% (d), 51–75% (e) and 76–100% (f). Scale bars 100 μm
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(Sigma-Aldrich, St. Louis, USA) and T47D cells were
grown in RPMI medium 1640 (Sigma-Aldrich), both
supplemented with 10% fetal bovine serum (FBS, Invi-
trogen, Carlsbad, USA), 2 mM L-glutamine (Invitrogen),
50 IU/ml penicillin and 50 μg/ml streptomycin sulphate
(Invitrogen). Cells were maintained in 5% CO2 at 37°C
in a cell culture incubator (Sanyo Electric Co, Osaka,
Japan). The cell lines were confirmed to be free of
Mycoplasma contamination (MycoAlert Mycoplasma
Detection Kit, Lonza, Rockland, USA).
siRNA mediated gene knockdown
Two Silencer Select siRNAs targeting ANLN, s28983
(siRNA 1) and s28984 (siRNA 2) (Ambion, Applied Biosys-
tems, Foster City, USA) were used to deplete the expression
of ANLN in SKBR3 and T47D cells. A non-targeting siRNA,
s229174, (Ambion) was used as control. Cells were seeded
in antibiotic-free medium into six-well plates or eight-well
glass chamber slides 24 h prior to siRNA transfection that
was done as instructed by the manufacturer using Lipofecta-
mine RNAiMAX (Invitrogen) as transfection reagent.
Statistical analysis of transcriptomics data
The publically available Cancer Genome Atlas database
(http://cancergenome.nih.gov/), including human tran-
scriptomics data based on mRNA sequencing (RNA-
Seq) was used to extract data for 664 patients with inva-
sive breast cancer and clinical survival data. A log rank
test was used to analyze the correlation between ANLN
expression and patient survival. Tumor samples were
stratified into two groups using the median Reads Per
Kilobase of transcript per Million mapped reads (RPKM)
value for ANLN as cut-off for a Kaplan-Meier estimate.
Cell cycle analysis
Growth medium and subconfluent cells were collected,
washed in PBS and fixed in ice-cold 70% ethanol at 4°C
over night. Cells were then washed twice in ice-cold PBS,
stained with 20 μg/ml propidium iodide (PI, Sigma-
Aldrich) in PBS, supplemented with 60 μg/ml RNAse A
(Sigma-Aldrich), for 30 min at room temperature and ana-
lyzed with a BD LSR II multi-laser analytical flow cytometer
(BD Biosciences). Cell cycle data was analyzed by ModFit
LT 3.2 software (Verity Software House, Topsham, USA).
Immunofluorescence
Following siRNA transfection in eight-well glass cham-
bers slides (BD Biosciences, Bedford, USA), cells were
fixed in 4% paraformaldehyde for ten minutes at room
temperature, permeabilized with 0.2% Triton X-100 for
20 min at room temperature and blocked in 5% normal
goat serum for one hour at room temperature. The pri-
mary ANLN antibody (Atlas Antibodies) was added
(dilution 1:100) and cell slides incubated at 4°C over night.
For signal detection, a secondary anti-rabbit antibody conju-
gated to fluorescein isothiocyanate (FITC) (Jackson Immu-
noResearch, West Grove, USA) was added and incubated
for 1 h at room temperature. Actin filaments were stained
with Phalloidin-Tetramethylrhodamine (TRITC) (Sigma-Al-
drich) for 40 min at room temperature and the slides
mounted with 4′,6-Diamidino-2-phenylindole (DAPI)-con-
taining mounting medium (Thermo Fisher Scientific). All
images were acquired with a Zeiss 510 confocal microscope
using the 40X objective (Zeiss, Oberkochen, Germany).
Senescence assay
Cellular senescence was detected using a commercially
available senescence β-galactosidase staining kit (Cell
Signaling Technology, Danvers, USA), according to the
manufacturer’s guidelines. Briefly, fixative solution was
applied for ten minutes at room temperature, the cells
rinsed with PBS and incubated in β-Galactosidase
Staining Solution at 37°C for approximately 12 h. The
number of senescent cells was counted in three separate
fields at 20x magnification. All images were acquired
with a Nikon camera using the 20X objective and Infin-
ity analyze 6.2.0 software (Lumenera, Ottawa, Canada).
Western blot
Total cellular protein was extracted with radio-immuno
precipitation assay (RIPA) buffer (Sigma-Aldrich) supple-
mented with protease inhibitors (Sigma-Aldrich) 72 and
120 h after siRNA-transfection. Protein concentration was
estimated with a Bicinchoninic Acid (BCA) Kit for Protein
Determination (Sigma-Aldrich). Protein lysates were sepa-
rated on 4–20% Criterion TGX Precast SDS-PAGE Gels
(Bio-Rad Laboratories, Hercules, USA) and blotted onto
PVDF membranes (Bio-Rad). Membranes were blocked
with 5% milk in Tris-buffered saline containing 0.5%
Tween-20 for 1 h followed by primary antibody incuba-
tion at 4°C over night. Membranes were incubated with
species specific horse radish peroxidase (HRP)-conjugated
secondary antibodies (DAKO) at room temperature for
1 h and developed with Immobilon Western Chemilumin-
escent HRP Substrate (Millipore, Billerica USA). Chemilu-
minescence was detected using a CCD-camera (Bio-Rad).
Statistical analysis
Spearman’s correlation test was used to evaluate correl-
ation between ANLN NF and NI. Differences in distribu-
tion between ANLN expression and clinicopathological
parameters were evaluated by means of the Chi-square
test and Fisher’s exact test for categorical and catego-
rized variables and for ordinal variables with more than
two categories a linear-by-linear test for association was
used. The Kaplan-Meier method and log-rank test was
used to illustrate differences in survival according to ANLN
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mRNA and protein expression. The Cox regression propor-
tional hazardsmodelwas used to estimate the impact ofANLN
on overall survival (OS), BCSS andRFS in univariable andmul-
tivariable analysis. The student t-test was used to determine the
significance of functional differences between various experi-
mental conditions during in vitro experiments. All in vitro data
representsmean values derived fromat least three independent
experiments. All statistical tests were two-sided and p-values
<0.05 considered significant. All calculations were performed
with Microsoft Office Excel 2007 (Microsoft, Redmond, USA)
or IBMSPSS Statistics version 22.0 (SPSS Inc. Illinois, USA).
Results
Nuclear fraction of ANLN expression is significantly
associated with clinicopathological parameters
To validate the relevance of ANLN as a prognostic marker
in breast cancer, ANLN protein expression was analyzed in
two independent TMA cohorts comprising of 144 (Cohort
Table 1 Correlation between ANLN expression and clinicopathological characteristics
Cohort I Cohort II










≤median 42 (67.7) 20 (32.3) 138 (68.0) 65 (32.0)
> median 32 (50.0) 32 (50.0) 0.043 110 (71.0) 45 (29.0) 0.544
Tumor size (mm)
≤ 20 42 (72.4) 16 (27.6) 99 (76.7) 30 (23.3)
> 20 32 (47.1) 36 (52.9) 0.004 149 (65.1) 80 (34.9) 0.021
ER status
Negative 6 (31.6) 13 (68.4) 50 (43.9) 64 (56.1)
Positive 68 (63.6) 39 (36.4) 0.009 191 (81.6) 43 (18.4) <0.001
PR status
Negative 15 (39.5) 23 (60.5) 46 (40.7) 67 (59.3)
Positive 59 (67.0) 29 (33.0) 0.004 188 (82.5) 40 (17.5) <0.001
Grade (NHG)
I 16 (100.0) 0 (0.0) 36 (97.3) 1 (2.7)
II 43 (74.1) 15 (25.9) 130 (86.7) 20 (13.3)
III 15 (28.8) 37 (71.2) <0.001 76 (47.2) 85 (52.8) <0.001
Nodal status
Negative 41 (63.1) 24 (36.9) 64 (66.0) 33 (34.0)
Positive 25 (49.0) 26 (51.0) 0.129 183 (70.4) 77 (29.6) 0.423
Ki-67
≤ 10% 50 (96.2) 2 (3.8) 101 (91.8) 9 (8.2)
> 10% 22 (30.6) 50 (69.4) <0.001 142 (59.4) 97 (40.6) <0.001
HER2 status
0–2+ 72 (61.5) 45 (38.5) 193 (70.4) 81 (29.6)
3+ 2 (22.2) 7 (77.8) 0.021 28 (58.3) 20 (41.7) 0.095
ER estrogen receptor, PR progesterone receptor, NHG Nottingham histological grade, HER2 human epidermal growth factor receptor 2
Age was defined as years at diagnosis. Positive ER and PR expression was considered as >10%. Chi square test, linear-by-linear test or Fisher’s exact test were used

























Cohort I Cohort II
Fig. 2 Distribution of ANLNnuclear fraction. Distributionof ANLNnuclear
fractionwas analyzed in two independent breast cancer cohorts. Themajority
of tumors investigated expressed less than 25%of ANLNnuclear staining
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I) and 564 (Cohort II) patients, respectively. As a conse-
quence of missing representative tumor tissue, the ANLN
expression status was evaluated in 126/144 (87.5%) tumors
in cohort I and in 358/564 (63.5%) tumors in cohort II.
Using Spearman’s correlation test, we found that ANLN NF
was significantly associated with ANLN NI (Cohort I: correl-
ation coefficient = 0.435, p < 0.001. Cohort II: correlation co-
efficient = 0.537, p < 0.001). A high percentage of primary
tumors (95.2% in cohort I and 82.1% in cohort II) displayed
moderate to strong nuclear intensity. The fraction of ANLN
positive tumor cells varied but the majority of cases showed
a NF < 25% (Fig. 2).
We investigated the potential association between ANLN
NF and various clinicopathological parameters by chi-square
test, linear-by-linear test or Fisher’s exact test and found that
tumors with a high ANLN NF were significantly associated
with an older age at diagnosis (Cohort I: p= 0.043), a larger
tumor size (Cohort I: p= 0.004. Cohort II: p = 0.021), hor-
mone receptor negativity (Cohort I: ER p= 0.009, PR p=
0.004. Cohort II: ER p < 0.001, PR p < 0.001), high tumor
grade (Cohort I: p < 0.001. Cohort II: p < 0.001), high expres-
sion of the cell proliferation marker Ki-67 (Cohort I: p <
0.001. Cohort II: p < 0.001) and HER2 positivity (Cohort I: p
= 0.021) (Table 1).
High ANLN nuclear fraction is associated with poor
patient survival
Next, we analyzed the relationship between ANLN expres-
sion and prognosis. In cohort I, breast cancer patients with
high ANLN NF had a significantly reduced OS (p= 0.022)
and BCSS (p= 0.044) (Fig. 3a, b). Kaplan-Meier analysis and
log-rank test for RFS showed a similar trend (Fig. 3c). Simi-
larly, a univariable cox regression model showed that high
ANLN NF was significantly associated with a reduced OS
(HR= 2.05; 1.10–3.82, 95% CI, p= 0.024) and this associ-
ation remained significant in multivariable analysis (HR =
1.93; 1.03–3.62, 95% CI, p= 0.039) when adjusted for age









































































































Fig. 3 Association of ANLN expression with survival. In cohort I, high ANLN nuclear fraction was significantly associated with a poor outcome in
overall survival (a) and breast cancer specific survival (b) but not in recurrence free survival (c). High ANLN nuclear fraction was significantly
correlated to a shorter overall survival (d), breast cancer specific survival (e) and recurrence free survival (f) in cohort II
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test revealed that breast cancer patients with high ANLN
NF had a significantly shorter OS (p < 0.001), BCSS (p <
0.001) and RFS (p < 0.001) than patients with a low ANLN
NF (Fig. 3d-f). These findings were also confirmed in a uni-
variable cox regression model (OS: HR = 1.91; 1.39–2.63,
95% CI, p < 0.001. BCSS: HR = 1.93; 1.38–2.69, 95%
CI, p < 0.001. RFS: HR = 1.75; 1.27–2.40, 95% CI, p = 0.001).
ANLN NF was also an independent predictor of OS (HR =
1.61; 1.09–2.39, 95% CI, p = 0.018), BCSS (HR = 1.58; 1.05–
2.38, 95% CI, p = 0.027) and RFS (HR = 1.67; 1.13–2.48,
95% CI, p = 0.010), when adjusted for Ki-67, tumor size,
hormone receptor status, HER2 status, nodal status and
age using multivariable cox regression models (Table 2).
ANLN is not a predictive marker for tamoxifen response
Tamoxifen, a Selective Estrogen Receptor Modulator
(SERM), functions as an anti-estrogen [24, 25] and is a
widely used adjuvant treatment for patients with early-
stage ER positive breast cancer [26, 27]. However, as not
all ER positive breast cancer patients respond to tamoxifen
treatment [28] and our finding of a strong correlation
between ANLN expression and ER status, the possible
Fig. 4 Association of ANLN mRNA expression with survival. Kaplan-Meier survival curve based on gene-expression data and survival information
from a publicly available DNA microarray dataset showed that high ANLN expression was significantly associated with poor survival
Table 2 Cox regression analysis of ANLN NF in relation to OS,
BCSS and RFS
Univariable analysis Multivariable analysis
HR (95% CI) p-value HR (95% CI) p-value
Cohort I
OS 2.05 (1.10–3.82) 0.024 1.93 (1.03–3.62) 0.039a
BCSS 2.34 (1.00–5.47) 0.051
RFS 1.88 (0.90–3.97) 0.095
Cohort II
OS 1.91 (1.39–2.63) <0.001 1.61 (1.09–2.39) 0.018b
BCSS 1.93 (1.38–2.69) <0.001 1.58 (1.05–2.38) 0.027b
RFS 1.75 (1.27–2.40) 0.001 1.67 (1.13–2.48) 0.010b
Low ANLN NF(ref) vs high ANLN NF
HR hazard ratio, CI confidence interval, ref referent group, ER estrogen
receptor, PR progesterone receptor, HER2 human epidermal growth factor
receptor 2
Significant correlations (p < 0.05) are indicated by bold numbers
aMultivariable analysis included adjustment for age
bMultivariable analysis included adjustment for Ki-67, tumor size, ER, PR, HER2,
nodal status and age
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association between ANLN expression and tamoxifen
response was explored. As the patients in cohort II had
been included in a randomized prospective tamoxifen
trial, we investigated the potential predictive value of
ANLN with regard to tamoxifen response in this cohort.
The distribution of ANLN NF was similar in the treatment
and control arms (Additional file 1: Figure S1). No signifi-
cant association was seen between ANLN NF and response
to tamoxifen treatment, when using Kaplan-Meier analysis
and log-rank test (Additional file 2: Figure S2).
Validation of ANLN protein expression on the transcript level
Analysis of the mRNA sequencing data (RNA-Seq) in the
Cancer Genome Atlas showed that breast cancer patients
with high expression of ANLN in tumor tissue had a
poorer prognosis as compared to patients with low levels
of ANLN. A Kaplan-Meier survival estimate, using the
median value of ANLN expression as cut-off, showed a
significant (p = 0.02) difference between patients with
tumors expressing high and low levels of ANLN, res-
pectively (Fig. 4). The 5-year survival for the ANLN high
group was 74% as compared to 85% for the ANLN low
group.
ANLN depletion leads to cell cycle arrest and altered cell
morphology
All in vitro experiments were performed at least three times
and given results represent a mean value of these experi-
ments. To study the functional relevance of ANLN in
breast cancer cells, the expression of ANLN was suppressed
in two independent breast cancer cell lines, SKBR3 and
T47D, using siRNA-mediated gene knockdown. The distri-
bution of cells in the cell cycle was measured as ANLN has
been reported as an important mediator of cell cycle pro-
gression. Flow cytometry-generated data showed a signifi-
cant accumulation of cells in the G2/M phase of the cell
cycle 3 days following siRNA transfection in both SKBR3
and T47D cells (Fig. 5). A similar, although not significant,
accumulation of cells in the G2/M phase was observed in
both cell lines analyzed 5 days after siRNA knockdown of
ANLN (Additional file 3: Figure S3). Analysis of cells with
reduced expression of ANLN by immunofluorescent stain-
ing showed a marked increase in the appearance of large,
poly-nucleated cells (Fig. 6 and Additional file 4: Figure S4).
ANLN depletion induces cellular senescence
As the altered cell morphology was indicative of cellular

































































































ANLN siRNA 1 ANLN siRNA 2
Fig. 5 Association of ANLN expression with cell cycle arrest. Flow cytometry-generated data showed that ANLN depletion lead to a significant
accumulation of cells in the G2/M phase of the cell cycle 3 days after siRNA knockdown, in both SKBR3 and T47D cells
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a β-galactosidase staining assay. The analysis confirmed
that the knockdown of ANLN expression induced signifi-
cant levels of cellular senescence compared to control
cells in SKBR3 cells, both 3 and 5 days after initiation of
ANLN depletion (Fig. 7 and Additional file 5: Figure S5).
Similar findings were observed for T47D cells, although
the increase of senescent cells was only significant for
ANLN siRNA2 five days after ANLN knockdown.
ANLN knockdown leads to decreased cyclin expression
A potential correlation between ANLN expression and
the cell cycle associated proteins cyclin D1, A2 and B1
was investigated to further study the role of ANLN in the
cell cycle. The dynamics and levels of decreased cyclin
expression varied between cell lines and time points
(Fig. 8). Using Spearman’s correlation test on IHC data
from cohort II we found that ANLN NI was significantly
correlated to cyclin D1 expression (Cyclin D1 NF: correl-
ation coefficient = 0.130, p = 0.015. Cyclin D1 NI: correl-
ation coefficient = 0.142, p = 0.008). Three days after
inducing a transient knockdown of ANLN in SKBR3 cells,
a reduced western blot signal for cyclin D1 was noted. In
T47D cells, a weaker signal for cyclin D1 was seen up to 5
days after knockdown. ANLN siRNA knockdown also re-
sulted in a reduction of cyclin A2 in both cell lines, which
was maintained up to 5 days, although this was most evi-
dent in T47D cells. For cyclin B1, ANLN siRNA reduced
the western blot signal in T47D cells up to 5 days after
Fig. 6 Influence of ANLN on cell morphology. Immunofluorescent staining of SKBR3 and T47D breast cancer cell lines showed efficient
knockdown of ANLN nuclear expression by two different siRNAs. ANLN siRNA knockdown induced a larger cell size and cells with multiple nuclei
compared to controls in both cell lines examined. ANLN was stained with FITC (green), nuclei were stained with DAPI (blue) and actin filaments
were stained with TRITC (red). Scale bars 30 μm
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knockdown while the signal reduction in SKBR3 cells was
more evident after 3 days.
Discussion
The identification of novel prognostic and predictive factors
is crucial for the development of personalized medicine for
cancer patients. The present study aimed at further exam-
ining the prognostic value and functional role of ANLN in
breast cancer. O’Leary et al [13] showed that a high ANLN
intensity was associated with poor prognosis in breast
cancer patients. The IHC based ANLN expression data in
the present study is well consistent with these findings,
however, our data are based on manual assessment of the
fraction of positive tumor cells which appears superior and
a more robust, reproducible and convenient assessment as
compared with estimating IHC intensities.
Two independent breast cancer patient cohorts were used
to investigate the potential impact of ANLN expression on
survival. In both TMA cohorts, a high nuclear fraction of
ANLN was significantly associated with a poor OS when
adjusted for well-known clinicopathological factors, using
multivariable cox regression models. Furthermore, in the
larger cohort II, multivariable cox regression analysis
showed that a high nuclear fraction of ANLN was signifi-
cantly associated with a reduced BCSS and RFS independent
of the cell proliferation marker Ki-67, tumor size, hormone
receptor status, HER2 status, nodal status and age. However,
in cohort I, ANLN nuclear fraction was not significantly as-
sociated with BCSS nor RFS, which may be due to the low
Fig. 7 Association of ANLN expression with senescence. Transient knockdown of ANLN expression induced significant levels of cellular
senescence compared to control in SKBR3 cells up to 5 days after initiation of ANLN depletion. Similar, but not significant, result was observed for
T47D cells. Scale bars 60 μm
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number of events for BCSS and RFS in this comparatively
small patient cohort. Our results based on immunohisto-
chemistry and ANLN protein expression are consistent with
findings on the transcript level. Based on quantitative RNA-
Seq data available from the Cancer Genome Atlas we
showed that high levels of ANLN mRNA in breast cancer
tissue were associated with shorter survival of patients as
compared to patients with low levels of ANLN mRNA.
These findings are also in agreement with a previous study
on breast cancer patients showing ANLN as a gene associ-
ated with increased risk for recurrence of breast cancer [29].
Overall, our cohort data and the results from transcripto-
mics analyses support the finding that ANLN is a strong in-
dependent prognostic biomarker for breast cancer.
IHC combined with tissue microarrays containing well-
characterized tumors provide an attractive strategy for both
discovery and validation of new cancer biomarkers [30].
Despite the obvious need for improved patient stratification
and numerous studies suggesting novel cancer biomarkers,
clinical decision making is at large dependent on morpho-
logical assessment and IHC staining based on proliferation
(Ki-67), hormone receptor status and expression of HER2
[31]. The expression pattern of the ANLN protein, based
on several validated antibodies also including the antibody
used in the present study, is presented in the Human Pro-
tein Atlas (www.proteinatlas.org) in a multitude of human
normal and cancer tissues. The Human Protein Atlas pro-
vides gene expression data on both the mRNA and protein
level, including underlying IHC-based images, for a vast
majority of all human protein coding genes [22, 32, 33].
Our results show that IHC-based ANLN expression pro-
vides a distinct and reproducible staining pattern, suggest-
ing a role as supplement to the prognostic breast cancer
biomarkers currently used in the clinic.
Previous studies have shown that the ANLN protein is
involved in cytokinesis, more specifically in the formation
of the cleavage furrow during late anaphase and telophase
[3, 34, 35]. Similar to the recently published findings by
Zhou et al [14], we found that transient knockdown of
ANLN protein expression in breast cancer cell lines re-
sulted in a significant accumulation of cells in the G2/M
phase of the cell cycle. Although experiments performed
on only two different cell lines with differences in ER
expression do not allow for general conclusions, we found
that the impact of ANLN on these two breast cancer cells
were similar, independent of ER status. Similar to Zhou et
al we detected decreased expression of cyclin D1 in
response to ANLN depletion. However, in contrast to
Zhou et al, we also observed that transient ANLN knock-
down reduced levels of cyclin B1, which is needed for G2/
M transition, and Cyclin A2, involved in S/G2 transition.
The shift in cell cycle distribution was most likely caused
by an arrest of cells in G2/M phase, with cells being unable
to complete mitosis, resulting in large and multi-nucleated
(mainly double-nucleated) cells. This is consistent with a
previous study by Oegema et al [3], who observed slower
cell cleavage leading to furrow regression and multi-
nucleated cells in response to anti-ANLN antibody micro-
injection. In addition, Straight et al [35] also observed
multi-nucleated HeLa cells following treatment with ANLN
siRNA. The cell cycle findings also correlated well with the
increased number of senescent cells that we observed.
The result from the present study validates previous find-
ings of high nuclear expression of ANLN being associated
with a more aggressive breast cancer phenotype. It is note-
worthy that even high grade breast cancer with severe nu-
clear atypia can be void of ANLN expression and that
ANLN is a prognostic factor independent of proliferation
Fig. 8 Influence of ANLN on cell cycle associated proteins. Western
blot analysis showed efficient knockdown of ANLN expression by
two different siRNAs. Overall, ANLN siRNA knockdown resulted in
lower expression of cyclin D1, cyclin A2 and cyclin B1compared to
controls in SKBR3 and T47D breast cancer cell lines. B-actin was used
as a loading control
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(Ki-67 expression), suggesting possible additional roles for
ANLN not directly linked to cytokinesis. Although there
was a trend showing a possible treatment predictive value
of ANLN for tamoxifen treatment, the correlation between
ANLN expression and response to tamoxifen was not sig-
nificant. Nevertheless, breast cancer patients with a high
tumor-specific ANLN expression may benefit from more
aggressive treatment due to the apparent “poor prognosis”
phenotype associated with high ANLN expression.
Conclusions
In conclusion, our data shows that ANLN expression is a
strong prognostic factor in breast cancer and essential for
cell cycle progression. We also show that depletion of ANLN
induces cellular senescence in breast cancer cell lines.
Further prospective studies are needed to establish a poten-
tial role in the clinical management of breast cancer patients
with tumors showing a high level of ANLN expression.
Additional files
Additional file 1: Figure S1. Distribution of ANLN nuclear fraction with
regard to tamoxifen treatment. Distribution of ANLN nuclear fraction was
analyzed with regard to tamoxifen treatment in cohort II, a randomized
prospective tamoxifen trial. The distribution of ANLN nuclear fraction was
similar in the treatment and control arms with the majority of tumors
expressing less than 25% of ANLN nuclear staining. (PDF 25 kb)
Additional file 2: Figure S2. Association of ANLN expression with
tamoxifen response. The potential treatment predictive value of ANLN with
regard to tamoxifen response was investigated in cohort II, a randomized
prospective tamoxifen trial. ANLN nuclear fraction was not a significant
predictor of tamoxifen response as shown by overall survival (A, D) breast
cancer specific survival (B, E) or recurrence free survival (C, F). (PDF 50 kb)
Additional file 3: Figure S3. A. Association of ANLN expression with cell
cycle arrest in SKBR3 cells. Flow cytometry-generated data showed that ANLN
depletion lead to a significant accumulation of cells in the G2/M phase of the
cell cycle 3 days after siRNA knockdown in SKBR3 cells. This accumulation was
clearly visible but not statistically significant 5 days after ANLN siRNA knock-
down. B. Association of ANLN expression with cell cycle arrest in T47D cells.
Flow cytometry-generated data showed that ANLN depletion lead to a signifi-
cant accumulation of cells in the G2/M phase of the cell cycle 3 days after
siRNA knockdown in T47D cells. This accumulation was clearly visible but not
statistically significant 5 days after ANLN siRNA knockdown. (ZIP 146 kb)
Additional file 4: Figure S4. A. Influence of ANLN on cell morphology
in SKBR3 cells. Immunofluorescent staining of SKBR3 breast cancer cell
lines showed that ANLN siRNA knockdown induced a larger cell size and
cells with multiple nuclei compared to controls up to 5 days after
knockdown. ANLN was stained with FITC (green), nuclei were stained
with DAPI (blue) and actin filaments were stained with TRITC (red). Scale
bars 30 μm. B. Influence of ANLN on cell morphology in T47D cells.
Immunofluorescent staining of T47D breast cancer cell lines showed that
ANLN siRNA knockdown induced a larger cell size and cells with multiple
nuclei compared to controls up to 5 days after knockdown. ANLN was
stained with FITC (green), nuclei were stained with DAPI (blue) and actin
filaments were stained with TRITC (red). Scale bars 30 μm. (ZIP 4784 kb)
Additional file 5: Figure S5. Association of ANLN expression with
senescence. Transient knockdown of ANLN expression induced significant
levels of cellular senescence compared to controls in SKBR3 cells up to 5
days after initiation of ANLN depletion. Significant levels of cellular
senescence compared to controls were noted in T47D cells 5 days after
ANLN siRNA knockdown. Similar, but not significant, result was observed
3 days after knockdown. Scale bars 60 μm. (TIF 14662 kb)
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